Safinamide
Top View
- NCL JFC Minutes August 2017
- Xadago, INN-Safinamide
- Product Monograph Including Patient Medication Information
- Annual Report 2006 2006 Highlights
- 2017 New Drug Update
- Appendix B - Product Name Sorted by Applicant
- (12) United States Patent (10) Patent No.: US 8,076,515 B2 Barbanti Et Al
- Patil AJ and Suryawanshi MR. Review on Novel Monoamine Oxidase Inhibitors: a Clinician’S Guide
- PDL)/Non-Preferred Drug List (NPDL
- Medicaid List of Covered Drugs (Formulary)
- Antiparkinson's Agents
- Changes in Strategies in Managing Motor and Non-Motor Symptoms in Parkinson’S Disease
- XADAGO (Safinamide) Tablets, for Oral Use • May Cause Or Exacerbate Dyskinesia; Consider Levodopa Dose Reduction Initial U.S
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- DRUG TREATMENTS for Parkinson's
- Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs
- Safinamide Improves Non-Motor Symptoms Burden In
- FEP 5 Tier Rx Drug Formulary (607) Standard Option